|
|
Article: Altus Pharmaceuticals Successfully Completes Phase 1 Study of Long Acting Formulation of Recombinant Human Growth Hormone.
- Article from:
- Clinical Trials Week
- Article date:
- January 19, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announced that it has finished its data analysis from a recently completed ALTU-238 Phase 1 study. ALTU-238 is being developed as a subcutaneously administered, long acting formulation of recombinant human growth hormone that employs Altus' proprietary protein crystallization and formulation technology, for patients with growth hormone deficiencies (see also Altus Pharmaceuticals).
The ALTU-238 Phase 1c trial evaluated the safety, pharmacokinetic and pharmacodynamic (PK/PD) profile of a single dose of ALTU-238 compared to seven daily injections of Nutropin AQ. ALTU-238 was well tolerated in the one-week study that ...